A retrospective, multicenter study analysing retention rate of Il-1 Inhibitors in patients with Schnitzler-syndrome
Latest Information Update: 07 Feb 2022
Price :
$35 *
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary)
- Indications Schnitzler syndrome
- Focus Therapeutic Use
- 12 Jan 2022 Results published in the Clinical and Experimental Rheumatology
- 25 Jun 2021 New trial record
- 05 Jun 2021 Results (n=15) presented at the 22nd Annual Congress of the European League Against Rheumatism.